INDV INDIVIOR PLC

Indivior to Participate in Upcoming Investor Conferences

Indivior to Participate in Upcoming Investor Conferences

RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences:

  • Barclays 28th Annual Global Healthcare Conference – Miami, FL

    Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: .
  • 2026 Jefferies Biotech on the Beach Summit – Miami, FL

    Joe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Wednesday, March 11th. Interested investors should contact their Jefferies representative to schedule a meeting.

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit  to learn more. Connect with Indivior on LinkedIn by visiting .

For Further Information

Investors:

Jason Thompson

Indivior Pharmaceuticals

Tel: 804-402-7123

E-mail:

Media:

Cassie France-Kelly

Indivior Pharmaceuticals

Tel: 804-594-0836

E-Mail:



EN
24/02/2026

Underlying

INDVINDIVIOR PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INDIVIOR PLC

 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance A...

February 26, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior to Participate in Upcoming Investor Conferences

Indivior to Participate in Upcoming Investor Conferences RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fires...

February 24, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results...

Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The w...

January 28, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior Announces Completion of Redomiciliation to the United States

Indivior Announces Completion of Redomiciliation to the United States RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation (“IPI”), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol “INDV.”The las...

January 26, 2026 1 EN
 PRESS RELEASE
Free
INDV INDIVIOR PLC

Indivior Provides Full-Year 2026 Financial Guidance and Business Updat...

Indivior Provides Full-Year 2026 Financial Guidance and Business Update Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE® Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected in the Range of $430 million to $450 millionAdjusted EBITDA Expected in the Range of $535 million to $575 million RICHMOND, Va., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced its full-year 2026 financial guidance. “2025 was a transition year for Indivior ...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch